Tolera Therapeutics - Bringing Targeted and Safer Therapies to Market

Developing Novel Therapies to Enhance Patients' Lives
Tolera Therapeutics is developing novel therapies and technologies, to offer patients and their doctors, targeted and safer solutions, for immune modulation and related medical needs. Learn about Short Course Immune Induction Therapy (SCIIT).

Markets

Developing more targeted and safer immune response therapies.

Organ transplant
Immune modulation
Oncology

Product Pipeline

Anti-rejection therapy
Induction therapy
Immune modulation
Oncology

Tolera News

Tolera Therapeutics granted Orphan Drug Designation for treatment of Type 1 diabetes mellitus
Tolera Therapeutics Honored as One of the 2010 “Michigan 50 Companies to Watch”
Tolera files IND application for TOL101, O'Toole to lead clinical operations
Tolera granted Orphan Drug Designation for organ transplant rejection drug
Related Articles...
Tolera Company Brochure

Learn About Short Course Immune Induction Therapy (SCIIT)

Home
About Us
Product Pipeline
News
Contact Us
Privacy Policy
Terms & Conditions